How much does Alpelisib cost as a targeted drug?

Alpelisib (Alpelisib)-Piqray is an oral targeted drug targeting PI3Kα mutations, developed by Novartis, for the treatment of patients with advanced or metastatic breast cancer carrying PIK3CA mutations. The emergence of this drug is regarded as an important breakthrough in tumor treatment, giving patients with abnormal activation of the PI3K signaling pathway for the first time a specific targeted treatment option. At present, the original drug of Apelvis has not been officially launched in mainland China, so its domestic pricing and medical insurance policies are still unclear. However, with the progress of import registration and the acceleration of domestic generic drug research and development, Apelvis is expected to enter the Chinese market and be included in the medical insurance negotiation sequence in the future.

In overseas markets, the price of Apelvis varies greatly depending on the place of origin and version. The specifications of the European version of the original drug are usually 56 tablets of 150mg, and the price per box may exceed 40,000 yuan, which is a high-end targeted drug pricing. The price of the Indian version of Apelvis (28 tablets of 150 mg of the same specification) is more cost-effective, with each box costing about 7,000 yuan.

In addition, the generic version (150mg*28 tablets) produced by the Lao pharmaceutical factory is sold in some international pharmacies, and the price per box is about 2,000 yuan, which significantly reduces the burden on patients compared with the original drug. Lao pharmaceutical companies usually produce legal generic versions based on original drug formulas, and their drug ingredients and efficacy are basically the same, making them the preferred alternative for many international patients.

From the perspective of global pharmaceutical market trends, the price of Apelvis is still affected by multiple factors, including exchange rate fluctuations, tariff policies, market competition, and pharmaceutical factory production capacity. Due to high research and development costs and long clinical trial cycles, the price of original drugs is generally high; the emergence of generic drugs has broken the monopoly of original drugs and made treatment more accessible. For patients who take targeted drugs for a long time, drug economy becomes an important factor affecting treatment compliance.

Reference materials:https://www.piqray.com/